TD Cowen raised the firm’s price target on Ultragenyx (RARE) to $73 from $61 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 earnings preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target raised to $83 from $73 at BofA
- Inozyme appoints Erik Harris to board of directors
- Ultragenyx receives Breakthrough Therapy Designation for setrusumab
- Ultragenyx provides update on Cyprus2+ study, to submit protocol amendment
- Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update